← Patent-cliff monitor small molecule VELSIPITY ETRASIMOD ARGININE
Loss of exclusivity June 2036 latest FDA-listed patent expiry
Company Pfizer → See this company's full patent-cliff portfolio Drug detail Brand name VELSIPITY Active ingredient ETRASIMOD ARGININE Strength EQ 2MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval October 2023 Marketing status RX
Listed patents Patent Expires Type 10676435 June 2036 use U-3731 10301262 June 2036 substance, product 11884626 June 2036 use U-3731 11091435 June 2036 substance, product 12377071 January 2036 use U-4255 11007175 January 2036 use U-3730 12156866 January 2036 use U-4047 8580841 March 2030 substance, product 9126932 July 2029 use U-3732
Regulatory exclusivity Code Expires NCE October 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.